Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

SCHERING-PLOUGH RECHRISTENS DRIXORAL SINUS as Drixoral Allergy Sinus, which will be introduced to the trade during the first quarter of 1994. Drixoral Allergy Sinus, Schering said, will be backed with "unprecedented" national media support including television and coupon drops in free-standing inserts. Drixoral Allergy Sinus will contain the same ingredients as Drixoral Sinus (acetaminophen 500 mg, pseudoephedrine 60 mg and dexbrompheniramine 3 mg) in the same 12-hour extended release tablet dosage form. The product will be available in packages of 12 and 24 tablets. Television ads will air during the spring and fall allergy seasons. Commercials featuring the new product will kick off in April 1994 and run through June. A second wave of ads will run from August through October. To complement the television spots, Schering has planned coupon drops for April 10 and Oct. 2 for free trial size packages of two tablets or 79" off a regular size package. Trial sizes will include in-package coupons for 50" off and consumers will be offered a try-it-free mail-in rebate for up to $ 5.50. In-store merchandising includes power wings and floorstands. The new name, Schering said, "invites consumers to use the product for allergy or sinus symptoms." Schering noted that allergy/sinus is the fastest-growing segment in the category, increasing 36% in dollar sales in 1993, as distinguished from products solely for allergy relief (up 20% in sales) or solely for sinus relief (up 9%). According to trade material, Schering projected that first year retail sales would reach $ 15 mil. Schering's material to the trade cites several instances where companies renamed their products and successfully "gave their sales new life." For instance, Johnson & Johnson changed the name of CoTylenol to Tylenol Cold; American Home Products changed the name of CoAdvil to Advil Cold & Sinus; Sandoz repositioned NeoCitran as TheraFlu; and P&G's DayQuil was formerly DayCare. Schering is attempting to revive the product against a growing number of allergy and sinus product introductions in the category. Since the spring 1992 Rx-to-OTC switch of Sandoz' Tavist (clemastine) and the successful retail launch of Tavist-D, the market has been flooded with new products. In the past year-and-a-half, Burroughs Wellcome introduced Actifed Sinus in July 1992, SmithKline Beecham began shipping Contac Day & Night Allergy and Sinus in December 1992 and Robins debuted Dimetapp Allergy in February. In addition, Whitehall repositioned CoAdvil as Advil Cold & Sinus in a move that emphasized the product was beneficial for sinus sufferers. More recently, Upjohn introduced Motrin IB Sinus in September ("The Tan Sheet, September 20, p. 3). Additionally, Upjohn is extending its line with Sine-Aid IB later this month and Burroughs Wellcome is introducing Actifed Allergy during the first quarter of 1994. The recent sinus and allergy product launches are reflected in data from Information Resources subsidiary Towne-Oller, which show that sinus analgesics had the third highest amount of new SKUs introduced from June 1992 to July 1993 among OTC categories. The new sinus product launches, according to Towne-Oller, represent nearly 20% of the total number of category SKUs on shelves and captured a 12.3% dollar share of the sinus category during the 12- month period.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts